# US 2023/0147035 A1 · Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0147035 A1
- Document ID: US20230147035A1
- Status: Published application
- Kind: A1
- Application number: 18/049,288
- Filed: 2022-10-24
- Published: 2023-05-11
- Earliest claimed: 2017-05-30
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Sangeeta Ray; Martin G. Pomper
- Web page: https://patentgrep.com/patent/US20230147035A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 51/0402: {carboxylic acid carriers, fatty acids (amino acids A61K51/0406)}
- A61K 51/0497: {conjugates with a carrier being an organic compounds}
- A61P 35/00: Antineoplastic agents
- C07B 59/002: {Heterocyclic compounds}
- C07D 257/02: not condensed with other rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07F 5/003: {without C-Metal linkages}
- C07F 7/24: Lead compounds
- C07B 2200/05: Isotopically modified compounds, e.g. labelled
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

## Claims

### Claim 1

A compound of Formula (I):
wherein:
Z is tetrazole or CO2Q;
Q is H or a protecting group;
m is an integer selected from the group consisting of 1, 2, 3, 4, and 5;
R is independently H or —CH2—R1;
R1 is selected from the group consisting of substituted aryl, substituted pyridine, and unsubstituted isoquinoline;
L is a linker selected from the group consisting of C1-C6 alkylene and C3-C6 cycloalkylene, and arylene;
W is selected from the group consisting of —NR2—(C═O)—, —NR2—(C═S)—, —(C═O)—NR2—, and —(C═S)—NR2—; wherein each occurrence of L and W can be the same or different;
R2 is H or a C1-C4 alkyl;
n is an integer selected from the group consisting of 1, 2, and 3;
Ch is a chelating agent that can comprise a metal or a radiometal;
and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group consisting of:
wherein X is independently Br or I.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the chelating agent is selected from the group consisting of:

### Claim 4 (depends on 1)

The compound of claim 1, wherein the metal chelating agent comprises a metal selected from the group consisting of: Y, Lu, Tc, Zr, In, Sm, Re, Cu, Pb, Ac, Bi, Al, Ga, Re, Ho and Sc.

### Claim 5 (depends on 4)

The compound of claim 4, wherein the metal is a radiometal and is selected from the group consisting of: 68Ga, 64Cu, 86Y, 90Y, 89Zr, 111In, 99mTc, 177Lu, 153Sm, 186Re, 188Re, 67Cu, 212Pb, 225Ac, 213Bi, 212Bi, 212Pb, 67Ga, 203Pb, 47Sc, and 166Ho.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound of Formula (I) is selected from the group consisting of:

### Claim 7

A method for treating one or more PSMA expressing tumors or cells, the method comprising contacting the one or more PSMA expressing tumors or cells with an effective amount of a compound of formula (I), the compound of formula (I) comprising:
wherein:
Z is tetrazole or CO2Q;
Q is H or a protecting group;
m is an integer selected from the group consisting of 1, 2, 3, 4, and 5;
R is independently H or —CH2—R1;
R1 is selected from the group consisting of substituted aryl, substituted pyridine, and unsubstituted isoquinoline;
L is a linker selected from the group consisting of C1-C6 alkylene and C3-C6 cycloalkylene, and arylene;
W is selected from the group consisting of —NR2—(C═O)—, —NR2—(C═S)—, —(C═O)—NR2—, and —(C═S)—NR2—; wherein each occurrence of L and W can be the same or different;
R2 is H or a C1-C4 alkyl;
n is an integer selected from the group consisting of 1, 2, and 3;
Ch is a chelating agent that comprises a radiometal suitable for radiotherapy;
and pharmaceutically acceptable salts thereof.

### Claim 8 (depends on 7)

The method of claim 7, wherein R1 is selected from the group consisting of:
wherein X is independently Br or I.

### Claim 9 (depends on 7)

The method of claim 7, wherein the chelating agent is selected from the group consisting of:

### Claim 10 (depends on 7)

The method of claim 7, wherein the radiometal is selected from the group consisting of: 90Y 177Lu, 211At 111In, 153Sm, 186Re, 188Re, 67Cu, 212Pb, 225Ac, 213Bi, 212Bi, 212Pb, and 67Ga.

### Claim 11 (depends on 7)

The method of claim 7, wherein the compound is selected from the group consisting of:

### Claim 12 (depends on 7)

The method of claim 7, wherein the one or more PSMA-expressing tumor or cell is selected from the group consisting of: a prostate tumor or cell, a metastasized prostate tumor or cell, a lung tumor or cell, a renal tumor or cell, a glioblastoma, a pancreatic tumor or cell, a bladder tumor or cell, a sarcoma, a melanoma, a breast tumor or cell, a colon tumor or cell, a germ cell, a pheochromocytoma, an esophageal tumor or cell, a stomach tumor or cell, and combinations thereof.

### Claim 13 (depends on 7)

The method of claim 7, wherein the one or more PSMA-expressing tumor or cell is a prostate tumor or cell.

### Claim 14 (depends on 7)

The method of claim 7, wherein the one or more PSMA-expressing tumor or cell is in vitro, in vivo, or ex vivo.

### Claim 15 (depends on 7)

The method of claim 7, wherein the one or more PSMA-expressing tumor or cell is present in a subject.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject is human.

### Claim 17 (depends on 7)

The method of claim 7, wherein the method results in inhibition of the tumor growth.

### Claim 18 (depends on 1)

The compound of claim 1, wherein the compound of formula (I) is selected from the group consisting of:
wherein: X is H or 4-benzylbromine;
M is selected from the group consisting of 177Lu, 225Ac, 213Bi, and 203Pb.

### Claim 19 (depends on 7)

The method of claim 7, wherein the compound of formula (I) is selected from the group consisting of:
wherein: X is H or 4-benzylbromine; and
M is selected from the group consisting of 177Lu, 225Ac, 213Bi, and 203Pb.
